Pharma Stocks Tumble: US Policy Shock & FDA Heat Drag Sector Down

Global Policy Pressure: US policy changes on drug pricing, especially the “most favored nation” clause, are raising serious concerns for Indian pharma exporters due to potential margin pressure. Regulatory Risk: Increased FDA scrutiny on overseas plants, especially Indian units, is hurting sentiment amid fears of stricter audits and warning letters. Nifty Pharma Index: Technically, the index broke below key short-term supports, showing weakness. Intraday charts reflect strong selling pressure with below-20 EMA closes on 5-min and 15-min timeframes. Stock-Specific Selling: Heavily US-dependent names like Sun Pharma, Lupin, Dr. Reddy's are underperforming, dragging the index down. Short-Term Outlook: Expect continued volatility as markets digest policy impact; avoid aggressive buying until a base forms and reversal candles are visible. Long-Term Watch: Investors may look for opportunities in companies with strong domestic presence or diversified exports beyond the US once the dust settles.